

# EPA BIOSOLIDS PFOA & PFOS PROBLEM FORMULATION MEETING – STAKEHOLDERS

---

Thursday, November 12, 2020

12:30-4:30 EST

Microsoft Teams meeting

## Agenda

---

|                            |  |
|----------------------------|--|
| 12:30-12:45 PM<br>(15 min) | <b>Welcome and Opening Remarks</b>   |
| 12:45-1:00 PM<br>(15 min)  | <b>Current Status and Purpose of the Meeting</b> <ul style="list-style-type: none"><li>• PFAS Action Plan</li><li>• Define Problem Formulation</li><li>• Purpose of the Risk Assessment</li></ul>  |
| 1:00-1:45 PM<br>(45 min)   | <b>Problem Formulation Part 1: Defining the Problem</b> <ul style="list-style-type: none"><li>• Chemical sources and occurrence; fate and transport in the environment; toxicity</li><li>• <u>Questions:</u><ul style="list-style-type: none"><li>○ <i>What sources of PFAS are you concerned about?</i></li><li>○ <i>Is your stakeholder group monitoring PFAS in biosolids, soils, surface or ground water?</i></li><li>○ <i>Are you collecting other information that you think would be useful to EPA?</i></li><li>○ <i>What challenges are you experiencing assessing the fate and transport of PFAS?</i></li><li>○ <i>Is there anything else you would like us to consider as we define the problem of PFOA and PFOS in biosolids?</i></li></ul></li></ul> |
| 1:45-2:30 PM<br>(45 min)   | <b>Problem Formulation Part 2: Conceptual Models</b> <ul style="list-style-type: none"><li>• Land application, surface disposal, and incineration</li><li>• <u>Questions:</u><ul style="list-style-type: none"><li>○ <i>Do the conceptual models capture the range of routes of exposure of concern for your stakeholder group? If not, what is missing?</i></li><li>○ <i>Do the conceptual models capture the range of receptors of concern for your stakeholder group? If not, what is missing?</i></li><li>○ <i>Do the conceptual models capture the range of potential health effects of concern for your stakeholder group? If not, what is missing?</i></li></ul></li></ul>  |
| 2:30-2:45 PM<br>(15 min)   | <b>Break</b>   |

|                                  |  |
|----------------------------------|--|
| <p>2:45-3:30 PM<br/>(45 min)</p> | <p><b>Problem Formulation Part 3: Analysis Plan</b></p> <ul style="list-style-type: none"> <li>● Toxicity endpoints for human health and wildlife</li> <li>● Modeling approach</li> <li>● <u>Questions:</u> <ul style="list-style-type: none"> <li>○ <i>Are you aware of reliable fate, transport, or toxicity data for various routes of exposure, receptors, or health effects that EPA should know about? If yes, please share.</i></li> <li>○ <i>Have you used any modeling approaches for PFAS that you would like to share with EPA?</i></li> <li>○ <i>Is there anything else you would like to share regarding modeling of PFOA and PFOS in biosolids?</i></li> </ul> </li> </ul> |
| <p>3:30-4:15 PM<br/>(45 min)</p> | <p><b>Risk Management and Implementation Considerations</b></p> <ul style="list-style-type: none"> <li>● If EPA determines that PFOA or PFOS in biosolids may adversely affect public health or the environment, risk management options will be considered.</li> <li>● <u>Questions:</u> <ul style="list-style-type: none"> <li>○ <i>What considerations or concerns should EPA be aware of during risk management and implementation?</i></li> <li>○ <i>Do you have any other topics related to risk management or implementation that you would like to raise?</i></li> </ul> </li> </ul>   |
| <p>4:15-4:30 PM<br/>(15 min)</p> | <p><b>Wrap Up</b></p>  |